Estenosis aórtica: prevalencia, directrices, nuevos tratamientos y datos actuales.

Estudios epidemiológicos han determinado que una de cada ocho personas de 75 años o mayores sufren de estenosis aórtica (EA) moderada o severa.1 Varios sondeos han mostrado que muchos pacientes con EA severa no se derivan a un equipo cardiológico para evaluar una sustitución de la válvula.2 La sustitución de válvula aórtica (SVA) quirúrgica es el criterio de referencia para el tratamiento de la EA severa y la implantación de la válvula aórtica transcatéter (TAVI) ofrece una nueva opción de tratamiento para aquellos pacientes considerados de alto riesgo para la cirugía.

http://solaci.org/es/pdfs/estenosis_medicos.pdf
SOLACI.ORG

Previous article
Next article

More articles by this author

Polymer-Free vs. Biodegradable Polymer Stents: SORT OUT IX 5-Year Outcomes

In a constant strive to achieve life time management, interventional cardiologists focus on optimizing coronary scaffolds, which calls for the development of devices with...

Chronic Stent Recoil and Its Long-Term Effects

The evolution of stent technology—including new scaffold designs, thinner struts, and more biocompatible polymers—has brought about an emerging concern: the late loss of structural...

iVAC2L: New Contribution to Ventricular Assist Devices in High Risk PCIs

The use of mechanical circulatory support (MCS) is on the rise, or increasingly necessary, seeing as high risk percutaneous coronary interventions (HR-PCIs) with severe...

Ischemia by Dobutamine Stress Echocardiography as a Predictor of PCI Efficacy

Patients with coronary artery disease (CAD) or chronic coronary syndromes (CCS) present a challenge in selecting the most adequate treatment, which entails correctly stratifying...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Polymer-Free vs. Biodegradable Polymer Stents: SORT OUT IX 5-Year Outcomes

In a constant strive to achieve life time management, interventional cardiologists focus on optimizing coronary scaffolds, which calls for the development of devices with...

Three-Year Outcomes of Mitral Valve-in-Valve Therapy with Balloon-Expandable Valves in the United States

Gentileza del Dr. Juan Manuel Pérez. Mitral Valve-in-Valve (MViV) implantation with balloon-expandable valves has become a solid alternative for patients with degenerated mitral bioprostheses. However,...

Edge-to-Edge Treatment in Cardiogenic Shock

Cardiogenic shock (CS) is characterized by severe ventricular dysfunction, most often of ischemic origin. It is frequently associated with severe mitral regurgitation (MR), either...